(Q37910841)

25 August 2017

1 reference

title

Limitations to the structure-based design of HIV-1 vaccine immunogens (English)

1 reference

25 August 2017

1 reference

Marc H V Van Regenmortel

series ordinal

1

1 reference

25 August 2017

publication date

1 September 2011

1 reference

Journal of Molecular Recognition

25 August 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 August 2017

volume

24

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

741-753

1 reference

HIV-1 neutralization: mechanisms and relevance to vaccine design

25 August 2017

cites work

1 reference

Toward an antibody-based HIV-1 vaccine

21 January 2018

1 reference

A proposal for the nomenclature of antigenic sites in peptides and proteins

21 January 2018

1 reference

What is a B-cell epitope?

21 January 2018

1 reference

Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab

21 January 2018

1 reference

Structural and functional approaches to the study of protein antigenicity

21 January 2018

1 reference

Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools

21 January 2018

1 reference

Immune epitope database analysis resource (IEDB-AR).

21 January 2018

1 reference

Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines.

21 January 2018

1 reference

Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies

21 January 2018

1 reference

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

21 January 2018

1 reference

Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles

21 January 2018

1 reference

Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology

21 January 2018

1 reference

Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry

21 January 2018

1 reference

Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents

21 January 2018

1 reference

Protection of cattle against foot-and-mouth disease by a synthetic peptide.

21 January 2018

1 reference

Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate

21 January 2018

1 reference

Mapping epitopes on the insulin molecule using monoclonal antibodies

21 January 2018

1 reference

The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS

21 January 2018

1 reference

Intrinsic and extrinsic factors in protein antigenic structure

21 January 2018

1 reference

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

21 January 2018

1 reference

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design

21 January 2018

1 reference

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

21 January 2018

1 reference

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

21 January 2018

1 reference

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

21 January 2018

1 reference

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

21 January 2018

1 reference

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors

21 January 2018

1 reference

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

21 January 2018

1 reference

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

21 January 2018

1 reference

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

21 January 2018

1 reference

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

21 January 2018

1 reference

The antigenic structure of the HIV gp120 envelope glycoprotein

21 January 2018

1 reference

Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs

21 January 2018

1 reference

Molecular architecture of native HIV-1 gp120 trimers

21 January 2018

1 reference

Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility

21 January 2018

1 reference

Challenges for structure-based HIV vaccine design

21 January 2018

1 reference

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

21 January 2018

1 reference

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

21 January 2018

1 reference

Structural definition of a conserved neutralization epitope on HIV-1 gp120

21 January 2018

1 reference

Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain

21 January 2018

1 reference

Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

21 January 2018

1 reference

Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop

21 January 2018

1 reference

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

21 January 2018

1 reference

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

21 January 2018

1 reference

Structure of a V3-containing HIV-1 gp120 core

21 January 2018

1 reference

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

21 January 2018

1 reference

Identifying epitopes of HIV-1 that induce protective antibodies

21 January 2018

1 reference

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

21 January 2018

1 reference

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

21 January 2018

1 reference

Cross-reactivity of monoclonal antibodies to a chimeric V3 peptide of HIV-1 with peptide analogues studied by biosensor technology and ELISA.

21 January 2018

1 reference

Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization

21 January 2018

1 reference

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

21 January 2018

1 reference

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

21 January 2018

1 reference

The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring

21 January 2018

1 reference

Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site

21 January 2018

1 reference

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

21 January 2018

1 reference

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10

21 January 2018

1 reference

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

21 January 2018

1 reference

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

21 January 2018

1 reference

The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes

21 January 2018

1 reference

A new paradigm in molecular recognition? Specific antibody binding to membrane-inserted HIV-1 epitopes.

21 January 2018

1 reference

A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies

21 January 2018

1 reference

The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.

21 January 2018

1 reference

Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions

21 January 2018

1 reference

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region

21 January 2018

1 reference

Role of HIV membrane in neutralization by two broadly neutralizing antibodies

21 January 2018

1 reference

Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity

21 January 2018

1 reference

HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane

21 January 2018

1 reference

Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding

21 January 2018

1 reference

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

21 January 2018

1 reference

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

21 January 2018

1 reference

Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking

21 January 2018

1 reference

The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection

21 January 2018

1 reference

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity

21 January 2018

1 reference

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis

21 January 2018

1 reference

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

21 January 2018

1 reference

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

21 January 2018

1 reference

Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies

21 January 2018

1 reference

Stabilization of the biologically active conformation of the principal neutralizing determinant of HIV-1(IIIB) containing a cis-proline surrogate: 1H NMR and molecular modeling study.

21 January 2018

1 reference

Antibody-antigen interactions: new structures and new conformational changes

21 January 2018

1 reference

Correlation between segmental mobility and the location of antigenic determinants in proteins

21 January 2018

1 reference

The atomic mobility component of protein antigenicity

21 January 2018

1 reference

Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling

21 January 2018

1 reference

Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus

21 January 2018

1 reference

Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations

21 January 2018

1 reference

Antibody multispecificity mediated by conformational diversity

21 January 2018

1 reference

Flexibility and molecular recognition in the immune system.

21 January 2018

1 reference

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

21 January 2018

1 reference

Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody

21 January 2018

1 reference

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

21 January 2018

1 reference

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

21 January 2018

1 reference

Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles

21 January 2018

1 reference

Current status of short synthetic peptides as vaccines

21 January 2018

1 reference

Polyreactivity of antibody molecules

21 January 2018

1 reference

Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies

21 January 2018

1 reference

Conformational changes associated with protein-protein interactions

21 January 2018

1 reference

Reductionism and the search for structure-function relationships in antibody molecules

21 January 2018

1 reference

Antibodies, viruses and vaccines

21 January 2018

1 reference

Reverse vaccinology, a genome-based approach to vaccine development

21 January 2018

1 reference

Genome-based approaches to develop vaccines against bacterial pathogens

21 January 2018

1 reference

Pathogen proteins eliciting antibodies do not share epitopes with host proteins: a bioinformatics approach

21 January 2018

1 reference

Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological and overcome the limitations of reductionism

21 January 2018

1 reference

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

21 January 2018

1 reference

Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology

21 January 2018

1 reference

Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects

21 January 2018

1 reference

Humoral immunity to HIV-1: neutralisation and antibody effector functions

21 January 2018

1 reference

Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?

21 January 2018

1 reference

Comparing antigenicity and immunogenicity of engineered gp120.

21 January 2018

1 reference

Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines

21 January 2018

1 reference

Specificities of broadly neutralizing anti-HIV-1 sera

21 January 2018

1 reference

Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses

21 January 2018

1 reference

A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine

21 January 2018

1 reference

Inactivation of viruses by aziridines

21 January 2018

1 reference

Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins

21 January 2018

1 reference

Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins

21 January 2018

1 reference

Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope

21 January 2018

1 reference

Virus-like particles: designing an effective AIDS vaccine

21 January 2018

1 reference

Virus-like particles as HIV-1 vaccines

21 January 2018

1 reference

21 January 2018

Spying on HIV with SPR.

1 reference

Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JMR.1116

1 reference

25 August 2017

1 reference